Nomura Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.55M | Buy |
56,651
+7,928
| +16% | +$1.18M | 0.02% | 481 |
|
|
2026
Q1 | $6.42M | Hold |
48,723
| – | – | 0.02% | 533 |
|
|
2025
Q4 | $6.91M | Hold |
48,723
| – | – | 0.02% | 527 |
|
|
2025
Q3 | $6.84M | Sell |
48,723
-250
| -0.5% | -$33.9K | 0.02% | 524 |
|
|
2025
Q2 | $6.16M | Sell |
48,973
-8,937
| -15% | -$1.02M | 0.02% | 550 |
|
|
2025
Q1 | $6.4M | Buy |
57,910
+4,284
| +8% | +$543K | 0.02% | 529 |
|
|
2024
Q4 | $7.32M | Sell |
53,626
-2,649
| -5% | -$328K | 0.02% | 490 |
|
|
2024
Q3 | $6.48M | Sell |
56,275
-1,473
| -3% | -$202K | 0.02% | 510 |
|
|
2024
Q2 | $7.95M | Sell |
57,748
-5,434
| -9% | -$745K | 0.03% | 428 |
|
|
2024
Q1 | $8.71M | Sell |
63,182
-423
| -0.7% | -$57.8K | 0.03% | 410 |
|
|
2023
Q4 | $8.38M | Buy |
63,605
+100
| +0.2% | +$11.5K | 0.03% | 404 |
|
|
2023
Q3 | $7.14M | Sell |
63,505
-5,580
| -8% | -$588K | 0.03% | 418 |
|
|
2023
Q2 | $6.51M | Buy |
69,085
+100
| +0.1% | +$9.77K | 0.03% | 444 |
|
|
2023
Q1 | $6.98M | Buy |
68,985
+32,756
| +90% | +$3.41M | 0.04% | 419 |
|
|
2022
Q4 | $4.33M | Buy |
36,229
+2,200
| +6% | +$258K | 0.03% | 490 |
|
|
2022
Q3 | $3.61M | Hold |
34,029
| – | – | 0.02% | 505 |
|
|
2022
Q2 | $3.32M | Buy |
34,029
+2,100
| +7% | +$194K | 0.02% | 565 |
|
|
2022
Q1 | $2.99M | Hold |
31,929
| – | – | 0.02% | 631 |
|
|
2021
Q4 | $2.72M | Buy |
31,929
+13,529
| +74% | +$1.24M | 0.01% | 671 |
|
|
2021
Q3 | $1.76M | Sell |
18,400
-13,209
| -42% | -$1.25M | 0.01% | 738 |
|
|
2021
Q2 | $3.08M | Buy |
31,609
+1,327
| +4% | +$127K | 0.02% | 617 |
|
|
2021
Q1 | $2.94M | Sell |
30,282
-1,082
| -3% | -$113K | 0.02% | 593 |
|
|
2020
Q4 | $3.01M | Buy |
31,364
+429
| +1% | +$41.4K | 0.02% | 565 |
|
|
2020
Q3 | $2.98M | Hold |
30,935
| – | – | 0.02% | 492 |
|
|
2020
Q2 | $3.77M | Buy |
30,935
+1,304
| +4% | +$144K | 0.03% | 417 |
|
|
2020
Q1 | $2.56M | Buy |
29,631
+1,400
| +5% | +$137K | 0.03% | 447 |
|
|
2019
Q4 | $3.04M | Buy |
28,231
+13,620
| +93% | +$1.43M | 0.03% | 475 |
|
|
2019
Q3 | $1.32M | Hold |
14,611
| – | – | 0.01% | 717 |
|
|
2019
Q2 | $1.23M | Hold |
14,611
| – | – | 0.01% | 725 |
|
|
2019
Q1 | $1.29M | Hold |
14,611
| – | – | 0.01% | 696 |
|
|
2018
Q4 | $1.04M | Hold |
14,611
| – | – | 0.01% | 688 |
|
|
2018
Q3 | $1.8M | Hold |
14,611
| – | – | 0.02% | 583 |
|
|
2018
Q2 | $1.44M | Hold |
14,611
| – | – | 0.01% | 650 |
|
|
2018
Q1 | $1.21M | Hold |
14,611
| – | – | 0.01% | 675 |
|
|
2017
Q4 | $1.13M | Hold |
14,611
| – | – | 0.01% | 694 |
|
|
2017
Q3 | $895K | Hold |
14,611
| – | – | 0.01% | 716 |
|
|
2017
Q2 | $672K | Hold |
14,611
| – | – | 0.01% | 782 |
|
|
2017
Q1 | $633K | Hold |
14,611
| – | – | 0.01% | 788 |
|
|
2016
Q4 | $565K | Hold |
14,611
| – | – | 0.01% | 805 |
|
|
2016
Q3 | $740K | Hold |
14,611
| – | – | 0.01% | 743 |
|
|
2016
Q2 | $664K | Sell |
14,611
-7,281
| -33% | -$335K | 0.01% | 745 |
|
|
2016
Q1 | $866K | Buy |
+21,892
| New | +$869K | 0.02% | 670 |
|
Other funds holding NBIX
Nomura Asset Management's NBIX Position: Q2 2026 in Review
Nomura Asset Management increased its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, buying an estimated $1.18M and bringing the position to 56,651 shares worth $9.55M. The position accounts for 0.02% of the portfolio, ranked #481.
Nomura Asset Management first reported a position in NBIX in Q1 2016 and has held it in 42 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Nomura Asset Management held 56,651 shares of Neurocrine Biosciences worth $9.55M as of Q2 2026.
- Nomura Asset Management bought 7,928 Neurocrine Biosciences shares in Q2 2026, an estimated $1.18M.
- Neurocrine Biosciences made up 0.02% of Nomura Asset Management's portfolio in Q2 2026, its #481 holding.
- Nomura Asset Management first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 42 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.